Welcome to the CancerBio Summer School and Cancer IO Special Sebinar on Hallmarks of Cancer: New Dimensions on 25 May at 13-14 EEST!
The event is organised in Zoom and is open to all interested in the topic.
Join the event: Zoom link.
Professor Douglas Hanahan
Douglas Hanahan, born in Seattle, Washington, USA, received a bachelor’s degree in Physics from MIT (1976), and a Ph.D. in Biophysics from Harvard (1983). He worked at Cold Spring Harbor Laboratory in New York (1978-88) initially as a graduate student and then as a group leader. From 1988-2010 he was on the faculty of the Department of Biochemistry & Biophysics at UCSF in San Francisco. Hanahan joined the Lausanne Branch of the Ludwig Institute for Cancer Research as a Distinguished Scholar in January 2020. In addition, Hanahan is currently Professor and Director of the Swiss Institute for Experimental Cancer Research within the School of Life Sciences at EPFL, the Swiss Federal Institute of Technology Lausanne and Co-director of the new multi-institutional Swiss Cancer Center Leman. He has been elected to the American Academy of Arts & Sciences (2007), the US Institute of Medicine (2008), the US National Academy of Science (2009), and EMBO (2010). Hanahan has also received an honorary degree from the University of Dundee in the UK (2011) and the Lifetime Achievement Award from the AACR (2014).
The Hanahan laboratory’s research program is structured around the use of genetically engineered mouse models (GEMMs) of multistep de novo tumorigenesis to investigate the hallmarks of cancer—the many distinct capabilities acquired by tumors and their constituent cells that are essential to the establishment and progression of cancers. The strategic plan is to elucidate the functional and phenotypic manifestations, molecular and cellular mechanisms, and regulation of hallmark capabilities—and to translate that knowledge into clinical applications, diagnostics and therapies. Currently Hanahan group investigates several organ-specific cancers, including ductal and neuroendocrine pancreatic cancers, cervical cancer, melanoma, metastatic breast cancer and glioblastoma. The group also have a robust program exploring the multiple mechanisms of immune evasion employed by tumors and strategies to disable such defenses to boost immunotherapy and broaden its applicability.
D. Hanahan. Hallmarks of Cancer: New Dimensions. Cancer Discovery. 2022-01-01. DOI : 10.1158/2159-8290.CD-21-1059.
S. Saghafinia; K. Homicsko; A. Di Domenico; S. Wullschleger; A. Perren, et al., D. Hanahan. Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression. Cancer Discovery. 2021-10-01. DOI : 10.1158/2159-8290.CD-20-1637.
Q. Zeng; I. P. Michael; P. Zhang; S. Saghafinia; G. Knott, et al., D. Hanahan. Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature. 2019-09-26. DOI : 10.1038/s41586-019-1576-6.
K. Shchors; A. Massaras; D. Hanahan. Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit. Cancer Cell. 2015. DOI : 10.1016/j.ccell.2015.08.012.
A. Sadanandam; C. A. Lyssiotis; K. Homicsko; E. A. Collisson; W. J. Gibb, et al., D. Hanahan. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nature Medicine. 2013. DOI : 10.1038/nm.3175.
Find out more information on Professor Hanahan’s research and recent publications: https://www.epfl.ch/labs/hanahan-lab/
CancerBio Summer School organizing team
Juha Klefström, Mariel Savelius, Krista Tuohinto, Meri Sieviläinen, James Clubb, Fernando Perez, Philipp Sergeev & Tatiana Kudling
Cancer IO team
Heidi Haikala, Juha Klefström & Mirjami Tran Minh